Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02505997 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02505997 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 22 participants.
The verdict
NCT02505997, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of repeated doses of oral delafloxacin on the pharmacokinetic (PK) profile of a single oral dose of midazolam.
Interventions
- DRUG Midazolam
- DRUG Delafloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02505997
The ClinicalTrials.gov registry entry for NCT02505997 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT02505997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02505997 about?
NCT02505997 is a clinical study titled "Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects". The purpose of this study is to evaluate the effect of repeated doses of oral delafloxacin on the pharmacokinetic (PK) profile of a single oral dose of midazolam.
What is the current status of trial NCT02505997?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02505997?
The interventions under investigation include: Midazolam (DRUG), Delafloxacin (DRUG).
Who is sponsoring clinical trial NCT02505997?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.